| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | K Uhland | |
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2968-78 | |
| P577 | publication date | 2006-12-01 | |
| P1433 | published in | Cellular and Molecular Life Sciences | Q5058352 |
| P1476 | title | Matriptase and its putative role in cancer | |
| P478 | volume | 63 |
| Q58108782 | 3-Cl-AHPC inhibits pro-HGF maturation by inducing matriptase/HAI-1 complex formation |
| Q50754826 | A Fluorescent-Labeled Phosphono Bisbenzguanidine As an Activity-Based Probe for Matriptase. |
| Q64058894 | A Novel Antibody-Toxin Conjugate to Treat Mantle Cell Lymphoma |
| Q37465276 | A large and accurate collection of peptidase cleavages in the MEROPS database |
| Q34683885 | A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer |
| Q33459231 | A sequence and structure based method to predict putative substrates, functions and regulatory networks of endo proteases |
| Q44771505 | AML/MDS with 11q/MLL amplification show characteristic gene expression signature and interplay of DNA copy number changes |
| Q55054374 | Activated matriptase as a target to treat breast cancer with a drug conjugate. |
| Q35740095 | Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase |
| Q46947626 | Autosomal ichthyosis with hypotrichosis syndrome displays low matriptase proteolytic activity and is phenocopied in ST14 hypomorphic mice |
| Q45741340 | Between two worlds: a comparative study on in vitro and in silico inhibition of trypsin and matriptase by redox-stable SFTI-1 variants at near physiological pH. |
| Q53099256 | Changing the selectivity profile - from substrate analog inhibitors of thrombin and factor Xa to potent matriptase inhibitors. |
| Q39437208 | Cleavage of hepatocyte growth factor activator inhibitor-1 by membrane-type MMP-1 activates matriptase |
| Q34165943 | Cleavage specificity analysis of six type II transmembrane serine proteases (TTSPs) using PICS with proteome-derived peptide libraries |
| Q58121061 | Co-expression of a Chimeric Protease Inhibitor Secreted by a Tumor-targeted Protects Therapeutic Proteins from Proteolytic Degradation |
| Q35023006 | Combinatorial optimization of cystine-knot peptides towards high-affinity inhibitors of human matriptase-1 |
| Q34567179 | Combinatorial tuning of peptidic drug candidates: high-affinity matriptase inhibitors through incremental structure-guided optimization |
| Q42038862 | Compact and modular multicolour fluorescence detector for droplet microfluidics |
| Q46167450 | Development of a Protease Biosensor Based on a Dimerization-Dependent Red Fluorescent Protein. |
| Q46033483 | Development of a periplasmic FRET screening method for protease inhibitory antibodies. |
| Q90695461 | Differential stromal reprogramming in benign and malignant naturally occurring canine mammary tumours identifies disease-modulating stromal components |
| Q37593021 | Differential tumorigenic potential and matriptase activation between PDGF B versus PDGF D in prostate cancer |
| Q34238503 | Diversity of matriptase expression level and function in breast cancer. |
| Q39242569 | Effects of Tepary bean (Phaseolus acutifolius) protease inhibitor and semipure lectin fractions on cancer cells |
| Q49545332 | Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein. |
| Q47249307 | Expansion of divergent SEA domains in cell surface proteins and nucleoporin 54. |
| Q33599461 | Expression and prognostic value of matriptase in ovarian serous adenocarcinoma |
| Q39943520 | Expression of hepatocyte growth factor activator inhibitor type 1 on the epithelial cell surface is regulated by hypoxic and oxidative stresses |
| Q53075335 | Expression of matriptase correlates with tumour progression and clinical prognosis in oral squamous cell carcinoma. |
| Q31071818 | From prediction to experimental validation: desmoglein 2 is a functionally relevant substrate of matriptase in epithelial cells and their reciprocal relationship is important for cell adhesion |
| Q38184632 | Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers |
| Q35041020 | HAI-2 suppresses the invasive growth and metastasis of prostate cancer through regulation of matriptase. |
| Q24321438 | Ichthyosis, follicular atrophoderma, and hypotrichosis caused by mutations in ST14 is associated with impaired profilaggrin processing |
| Q39671578 | Identification of the First Low-Molecular-Weight Inhibitors of Matriptase-2 |
| Q36512410 | Imaging a functional tumorigenic biomarker in the transformed epithelium |
| Q38771773 | Impact of suppression of tumorigenicity 14 (ST14)/serine protease 14 (Prss14) expression analysis on the prognosis and management of estrogen receptor negative breast cancer |
| Q51075784 | Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis. |
| Q41661853 | Kempopeptin C, a Novel Marine-Derived Serine Protease Inhibitor Targeting Invasive Breast Cancer |
| Q30540234 | Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells. |
| Q42945644 | Loss of the matriptase inhibitor HAI‐2 during prostate cancer progression |
| Q37218017 | Matriptase activation and shedding through PDGF-D-mediated extracellular acidosis |
| Q30424187 | Matriptase, HAT, and TMPRSS2 activate the hemagglutinin of H9N2 influenza A viruses |
| Q44899123 | Matriptase-2 inhibits HECV motility and tubule formation in vitro and tumour angiogenesis in vivo |
| Q35895533 | Mechanisms for the control of matriptase activity in the absence of sufficient HAI-1 |
| Q43211711 | Metabolism and distribution of two highly potent and selective peptidomimetic inhibitors of matriptase |
| Q28238739 | Novel surface targets and serum biomarkers from the ovarian cancer vasculature |
| Q39061621 | Overexpression of matriptase correlates with poor prognosis in esophageal squamous cell carcinoma |
| Q92048491 | Post-ER Stress Biogenesis of Golgi Is Governed by Giantin |
| Q96683469 | Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody |
| Q34094496 | Proteolytic cleavage of human acid-sensing ion channel 1 by the serine protease matriptase |
| Q39697447 | Proteolytic processing of the serine protease matriptase-2: identification of the cleavage sites required for its autocatalytic release from the cell surface |
| Q36508121 | Quantification of the N-glycosylated secretome by super-SILAC during breast cancer progression and in human blood samples |
| Q35956447 | Role of IGFBP7 in Diabetic Nephropathy: TGF-β1 Induces IGFBP7 via Smad2/4 in Human Renal Proximal Tubular Epithelial Cells |
| Q33740667 | Sampling the N-terminal proteome of human blood |
| Q28077999 | Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins |
| Q92705253 | Targeting metastatic breast cancer with peptide epitopes derived from autocatalytic loop of Prss14/ST14 membrane serine protease and with monoclonal antibodies |
| Q34038504 | Targeting zymogen activation to control the matriptase-prostasin proteolytic cascade. |
| Q41027527 | The Impact of Acute Matriptase Inhibition in Hepatic Inflammatory Models. |
| Q47171613 | The Kunitz Domain I of Hepatocyte Growth Factor Activator Inhibitor-2 Inhibits Matriptase Activity and Invasive Ability of Human Prostate Cancer Cells |
| Q42080648 | The mechanism of inhibition of antibody-based inhibitors of membrane-type serine protease 1 (MT-SP1). |
| Q39015415 | The role of type II transmembrane serine protease-mediated signaling in cancer |
| Q47168535 | The serine proteinase hepsin is an activator of pro-matrix metalloproteinases: molecular mechanisms and implications for extracellular matrix turnover |
| Q42778244 | The type II transmembrane serine protease matriptase cleaves the amyloid precursor protein and reduces its processing to β amyloid |
| Q35016106 | Tissue-penetrating delivery of compounds and nanoparticles into tumors |
| Q33659444 | Tumor detection by imaging proteolytic activity |
| Q44705970 | Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index |
| Q33910850 | Type II transmembrane serine protease gene variants associate with breast cancer |
| Q83970549 | Type II transmembrane serine proteases |
| Q37712358 | Urokinase-controlled tumor penetrating peptide |
| Q34883707 | c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase |
Search more.